Clinical Trial Update: Avalglucosidase Alfa Extension Study [Phase 2]

View source ↗

Summary

Phase 2 extension study of avalglucosidase alfa for Pompe disease has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii Pompe Disease

Drugs mentioned

• Avalglucosidase alfa (avalglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II Pompe Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-03-01